HHS expands U.S.-based pharmaceutical manufacturing to get drugs to hospitals faster

May 21, 2020 / Susan Morse, Managing Editor

The Department of Health and Human Services will work with a team of private industry partners led by Phlow Corporation of Richmond, Virginia, to expand pharmaceutical manufacturing in the United States to provide medicines needed during COVID-19 and future public health emergencies.

The U.S. government and Phlow are developing a prioritized list of active pharmaceutical ingredients and finished medicines critically needed by healthcare systems.

The Phlow-led team will provide immediate, U.S.-based capacity to produce the active pharmaceutical ingredients and the chemical compounds for ingredients needed to help alleviate or prevent drug shortages.

The drug ingredients will be manufactured at facilities in the United States, including a new facility to be built in Virginia.


Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button